These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27194003)

  • 1. Rapid Absorption of Dry-Powder Intranasal Oxytocin.
    Milewski M; Goodey A; Lee D; Rimmer E; Saklatvala R; Koyama S; Iwashima M; Haruta S
    Pharm Res; 2016 Aug; 33(8):1936-44. PubMed ID: 27194003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
    Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
    Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and CSF oxytocin levels after intranasal and intravenous oxytocin in awake macaques.
    Freeman SM; Samineni S; Allen PC; Stockinger D; Bales KL; Hwa GG; Roberts JA
    Psychoneuroendocrinology; 2016 Apr; 66():185-94. PubMed ID: 26826355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.
    Quintana DS; Westlye LT; Hope S; Nærland T; Elvsåshagen T; Dørum E; Rustan Ø; Valstad M; Rezvaya L; Lishaugen H; Stensønes E; Yaqub S; Smerud KT; Mahmoud RA; Djupesland PG; Andreassen OA
    Transl Psychiatry; 2017 May; 7(5):e1136. PubMed ID: 28534875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective absorption behavior of insulin for diabetic treatment following intranasal delivery using porous spherical calcium carbonate in monkeys and healthy human volunteers.
    Haruta S; Hanafusa T; Fukase H; Miyajima H; Oki T
    Diabetes Technol Ther; 2003; 5(1):1-9. PubMed ID: 12725701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.
    Bancke LL; Dworak HA; Rodvold KA; Halvorsen MB; Gidal BE
    Epilepsia; 2015 Nov; 56(11):1723-31. PubMed ID: 26332539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized four-way crossover trial with nasal cavity dimension assessment.
    Quintana DS; Westlye LT; Rustan ØG; Tesli N; Poppy CL; Smevik H; Tesli M; Røine M; Mahmoud RA; Smerud KT; Djupesland PG; Andreassen OA
    Transl Psychiatry; 2015 Jul; 5(7):e602. PubMed ID: 26171983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxytocin and Migraine Headache.
    Tzabazis A; Kori S; Mechanic J; Miller J; Pascual C; Manering N; Carson D; Klukinov M; Spierings E; Jacobs D; Cuellar J; Frey WH; Hanson L; Angst M; Yeomans DC
    Headache; 2017 May; 57 Suppl 2():64-75. PubMed ID: 28485846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation.
    Pozzoli M; Rogueda P; Zhu B; Smith T; Young PM; Traini D; Sonvico F
    Drug Dev Ind Pharm; 2016 Oct; 42(10):1660-8. PubMed ID: 26953090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep.
    Hinchcliffe M; Jabbal-Gill I; Smith A
    J Pharm Pharmacol; 2005 Jun; 57(6):681-7. PubMed ID: 15969922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
    Luthringer R; Djupesland PG; Sheldrake CD; Flint A; Boeijinga P; Danjou P; Demazières A; Hewson G
    J Pharm Pharmacol; 2009 Sep; 61(9):1219-28. PubMed ID: 19703372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
    Wermeling DP; Record KA; Archer SM; Rudy AC
    Epilepsy Res; 2009 Feb; 83(2-3):124-32. PubMed ID: 19046855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial.
    Kosaka H; Okamoto Y; Munesue T; Yamasue H; Inohara K; Fujioka T; Anme T; Orisaka M; Ishitobi M; Jung M; Fujisawa TX; Tanaka S; Arai S; Asano M; Saito DN; Sadato N; Tomoda A; Omori M; Sato M; Okazawa H; Higashida H; Wada Y
    Transl Psychiatry; 2016 Aug; 6(8):e872. PubMed ID: 27552585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of solubility enhancement on nasal absorption of meloxicam.
    Horváth T; Ambrus R; Völgyi G; Budai-Szűcs M; Márki Á; Sipos P; Bartos C; Seres AB; Sztojkov-Ivanov A; Takács-Novák K; Csányi E; Gáspár R; Szabó-Révész P
    Eur J Pharm Sci; 2016 Dec; 95():96-102. PubMed ID: 27260088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasal Drug Absorption from Powder Formulations: Effect of Fluid Volume Changes on the Mucosal Surface.
    Tanaka A; Furubayashi T; Enomura Y; Hori T; Shimomura R; Maeda C; Kimura S; Inoue D; Kusamori K; Katsumi H; Sakane T; Yamamoto A
    Biol Pharm Bull; 2017; 40(2):212-219. PubMed ID: 28154262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intranasal administration of oxytocin on fear recognition.
    Fischer-Shofty M; Shamay-Tsoory SG; Harari H; Levkovitz Y
    Neuropsychologia; 2010 Jan; 48(1):179-84. PubMed ID: 19747930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain.
    Ved PM; Kim K
    Int J Pharm; 2011 Jun; 411(1-2):1-9. PubMed ID: 21356294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations.
    Cheng YH; Dyer AM; Jabbal-Gill I; Hinchcliffe M; Nankervis R; Smith A; Watts P
    Eur J Pharm Sci; 2005 Sep; 26(1):9-15. PubMed ID: 15970435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
    Reddy MB; Connor A; Brennan BJ; Morcos PN; Zhou A; McLawhon P; Fretland A; Evans P; Smith P; Tran JQ
    Biopharm Drug Dispos; 2011 Jul; 32(5):261-75. PubMed ID: 21660978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.